Caroline Ricce Espada

• Abstract

  During its life cycle, the digenetic parasite Leishmania colonizes hostile environments with different physiological characteristics, requiring precision in the modulation of gene expression. Its genetic organization with peculiar characteristics, such as the lack of canonical promoters for RNA Polymerase II, the transcription of unrelated genes in polycistronic units, and the processing …

  Functional validation of potential non-coding RNAs differentially expressed during Leishmania viannia braziliensis life cycle, BP.PD

• Abstract

  Leishmania (Viannia) braziliensis is the main etiological agent of Cutaneous Leishmaniasis in Brazil, where in 2014 approximately 21,000 new cases of the disease were notified. The arsenal available for treatment is limited due to parenteral administration, toxicity, high cost, and emergence of resistance. Miltefosine is the only oral drug approved for the treatment of Cutaneous and Visce…

  Susceptibility to miltefosine in Leishmania (Viannia) braziliensis clinical isolates: phenotypic characterization and investigation of the basis involved in reduced susceptibility to the drug, BP.DD

• Abstract

  Leishmaniasis is a disease caused by parasites of Leishmania genus. In Brazil, the cutaneous form of the disease is mainly caused by Leishmania (V.) braziliensis, with an annual incidence of approximately 26,000 cases in 2012. The drugs available for the treatment of leishmaniasis have limitations as high toxicity and the need of parenteral administration, which can result in interruption…

  Characterization of Leishmania (v.) braziliensis clinical isolates susceptibility to miltefosine in vitro and in vivo, BP.MS

(Only some records are available in English at this moment)

• Abstract

  During its lifecycle Leishmania needs to have a rapid shift in gene expression profile in order to adapt to environmental changes. Trypanosomatids lack canonical promoters for most of their genes and thus, regulation of gene expression results mostly from post-transcriptional processes. Differentially expressed (DE) non-protein coding RNAs (ncRNAs) have been identified in the transcriptom…

  Investigation of non-coding RNA-protein interactions in Leishmania (Viannia) braziliensis: identifying ligands and dissecting binding profiles, BE.EP.PD

• Abstract

  The first choice drug for cutaneous leishmaniasis treatment in Brazil, where Leishmania (Viannia) braziliensis is the most prevalent etiological agent, is meglumine antimoniate, administered intravenously for 20 days. Success rates for antimonial therapy can be as low as 50% in some areas. As part of an effort to evaluate whether miltefosine would be applicable to leishmaiasis chemotherap…

  Investigating the role of Ros3 in differential susceptibility of Leishmania to miltefosine using a CRISPR/Cas9 approach, BE.EP.DD